KELSEY KINGSBOROUGH: Open Payments
NPI 1851942619 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,048 in 308 payments from 19 companies in 2025. Trend: 2023 $4,754 · 2024 $5,315 · 2025 $5,048
Food & beverage: $5,040Education: $9
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $609 |
| ABBVIE INC. | 41 | $553 |
| Neurocrine BioSciences, Inc. | 34 | $553 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 38 | $539 |
| E.R. Squibb & Sons, L.L.C. | 20 | $464 |
| Alkermes, Inc. | 24 | $441 |
| Axsome Therapeutics, Inc. | 21 | $367 |
| Corium, LLC | 23 | $262 |
| Supernus Pharmaceuticals, Inc. | 14 | $257 |
| Vanda Pharmaceuticals Inc. | 16 | $256 |
Products named: REXULTI, VRAYLAR, INGREZZA, CAPLYTA, COBENFY, ARISTADA, Auvelity, Azstarys.
Industry payments across MO — which companies pay providers there.
